drugset / Trial / NCT04500522

Vaginal Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients

NCT04500522 ↗

Phase 4 Completed 150 enrolled Aswan University Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To compare the effectiveness of vaginal isonicotinic acid hydrazide with placebo in minimizing the pain experienced by primarily infertile patients during diagnostic office hysteroscopy and to assess the ease of insertion of hysteroscope as reported by the hysteroscopist.

Timeline

Start
2020-09-01
Primary completion
2021-08-30
Completion
2021-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject INH Unknown 900 mg —

Indications